2 months ago
ABBV
AnalystsTerence FlynnTerence Flynn's Stock Forecasts
AnalystsTerence Flynn
Sectors:
Analyst Ranking
Top 11%
#540 out of 4922 analysts
Average Return
+10.39%
Win Rate
57%56 out of 98
Risk vs Reward
Poor
Good
Terence Flynn's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Translate Bio IncTBIO1 | +147.91% | $15.07 | $37.36 | 2020-10-05 - 2021-09-14 | Strong Buy |
Blueprint Medicines CorpBPMC | +140.20% | $41.34 | $99.30 | 2017-03-13 - 2018-03-13 | Strong Buy |
Eli Lilly & CoLLY | +139.90% | $314.17 | $753.68 | 2023-03-01 - 2024-02-29 | Strong Buy |
Eli Lilly & CoLLY | +106.33% | $367.00 | $757.24 | 2023-04-10 - 2024-04-09 | Strong Buy |
Eli Lilly & CoLLY | +96.90% | $339.08 | $667.65 | 2023-02-03 - 2024-02-02 | Strong Buy |
Terence Flynn Analyst Color
Get additional color on Terence Flynn's coverage of popular stocks
2 months ago
JNJ
3 months ago
LLY
3 months ago
JNJ
3 months ago
ABBV
5 months ago
MRK
5 months ago
JNJ
8 months ago
ABBV
10 months ago
LLY
a year ago
RPRX
a year ago
ABBV
a year ago
LLY
a year ago
PFE
a year ago
LLY
2 years ago
PFE
2 years ago
JNJ
2 years ago
PFE
2 years ago
JNJ
2 years ago
LLY
3 years ago
JNJ
3 years ago
JNJ
3 years ago
PFE
3 years ago
MRK
3 years ago
JNJ
3 years ago
ABBV
Terence Flynn's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Arvinas IncARVN | 8 | Hold | $11.00 | +45.89% | Maintains | 2 months ago |
Arcus Biosciences IncRCUS | 6 | Strong Buy | $22.00 | +176.73% | Maintains | 2 months ago |
Biontech SeBNTX | 3 | Strong Buy | $132.00 | +23.69% | Maintains | 2 months ago |
Organon & CoOGN | 10 | Hold | $10.00 | +1.42% | Maintains | 2 months ago |
United Therapeutics CorpUTHR | 9 | Hold | $348.00 | +22.42% | Maintains | 2 months ago |
Abbvie IncABBV | 16 | Strong Buy | $250.00 | +37.13% | Maintains | 2 months ago |
Johnson & JohnsonJNJ | 21 | Hold | $169.00 | +10.89% | Maintains | 2 months ago |
Eli Lilly & CoLLY | 17 | Strong Buy | $1,124.00 | +44.95% | Maintains | 3 months ago |
Amgen IncAMGN | 8 | Hold | $330.00 | +19.08% | Maintains | 3 months ago |
Biohaven LtdBHVN | 2 | Strong Buy | $63.00 | +347.13% | Maintains | 4 months ago |
Crispr Therapeutics AgCRSP | 7 | Strong Sell | $32.00 | -32.62% | Maintains | 4 months ago |
Merck & Co IncMRK | 15 | Hold | $106.00 | +34.01% | Maintains | 5 months ago |
Nurix Therapeutics IncNRIX | 4 | Hold | $17.00 | +46.05% | Maintains | 5 months ago |
Intellia Therapeutics IncNTLA | 5 | Hold | $11.00 | +15.06% | Downgrades | 5 months ago |
Bristol Myers Squibb CoBMY | 9 | Strong Sell | $39.00 | -15.86% | Maintains | 8 months ago |
Pfizer IncPFE | 17 | Hold | $31.00 | +28.15% | Maintains | 8 months ago |
Structure Therapeutics IncGPCR | 1 | Strong Buy | $118.00 | +459.77% | Initiates Coverage On | 9 months ago |
Alumis IncALMS | 1 | Strong Buy | $36.00 | +1,092.05% | Initiates Coverage On | a year ago |
Royalty Pharma PLCRPRX | 11 | Strong Buy | $51.00 | +42.18% | Maintains | a year ago |
Blueprint Medicines CorpBPMC | 5 | Strong Buy | $168.00 | N/A | Maintains | a year ago |
C4 Therapeutics IncCCCC | 5 | Hold | $8.00 | N/A | Maintains | a year ago |
Revance Therapeutics IncRVNC | 7 | Hold | $12.00 | N/A | Maintains | 2 years ago |
Neuehealth IncNEUE | 1 | Strong Buy | $2,880.00 | N/A | Initiates Coverage On | 4 years ago |
Biogen IncBIIB | 2 | Hold | $436.00 | N/A | Maintains | 4 years ago |
Translate Bio IncTBIO1 | 1 | Strong Buy | $342.00 | N/A | Initiates Coverage On | 5 years ago |
Acceleron Pharma IncXLRN | 2 | Hold | $40.00 | N/A | Upgrades | 7 years ago |
Alnylam Pharmaceuticals IncALNY | 1 | Strong Buy | N/A | N/A | Upgrades | 8 years ago |
Fibrogen IncFGEN | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Bioverativ IncBIVV | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.